Lombard Odier Asset Management (USA)’s Regeneron Pharmaceuticals REGN Stock Holding History

Lombard Odier Asset Management (USA)’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-395	Closed	-$305K	–	249
2026 Q1	$305K	Buy	+395	New	+$302K	0.03%	185
2025 Q4	–	Sell	-746	Closed	-$419K	–	388
2025 Q3	$419K	Buy	746 +152	+26%	+$85.9K	0.03%	303
2025 Q2	$312K	Buy	+594	New	+$332K	0.02%	300
2020 Q4	–	Sell	-2,408	Closed	-$1.35M	–	310
2020 Q3	$1.35M	Buy	+2,408	New	+$1.46M	0.09%	169

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Lombard Odier Asset Management (USA)'s REGN Position: Q2 2026 in Review

Lombard Odier Asset Management (USA) sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 395 shares — an estimated $305K sold.

Lombard Odier Asset Management (USA) first reported a position in REGN in Q3 2020 and held it in 4 quarters. The position peaked at $1.35M in Q3 2020. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Lombard Odier Asset Management (USA) reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Lombard Odier Asset Management (USA) sold 395 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $305K.
Lombard Odier Asset Management (USA) first reported a position in Regeneron Pharmaceuticals in Q3 2020 and held it in 4 quarters.
Lombard Odier Asset Management (USA)'s Regeneron Pharmaceuticals position peaked at $1.35M in Q3 2020.
1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Lombard Odier Asset Management (USA)'s 13F filing for Q2 2026, filed 14 Aug 2026.